Celcuity Inc
CELC39.545USD
+1.045+2.71%
取引時間 （ET）15分遅れの株価
1.50B時価総額
損失額直近12ヶ月PER
詳細情報 Celcuity Inc 企業名
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.
企業情報
企業コードCELC
会社名Celcuity Inc
上場日Sep 20, 2017
設立日2017
最高経営責任者「CEO」Mr. Brian F. Sullivan
従業員数87
証券種類Ordinary Share
決算期末Sep 20
本社所在地16305 36th Ave N Ste 100
都市MINNEAPOLIS
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号55446-4285
電話番号17633920767
ウェブサイトhttps://www.celcuity.com/
企業コードCELC
上場日Sep 20, 2017
設立日2017
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Brian F. Sullivan
Mr. Brian F. Sullivan
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
3.02M
+0.27%
Mr. Richard J. Nigon
Mr. Richard J. Nigon
Independent Director
Independent Director
101.09K
--
Ms. Vicky Hahne, CPA
Ms. Vicky Hahne, CPA
Chief Financial Officer
Chief Financial Officer
18.86K
+1.63%
Dr. Richard E. Buller, M.D., Ph.D.
Dr. Richard E. Buller, M.D., Ph.D.
Independent Director
Independent Director
7.71K
-0.64%
Dr. Polly A. Murphy, DVM, Ph.D.
Dr. Polly A. Murphy, DVM, Ph.D.
Independent Director
Independent Director
5.00K
--
Dr. Lance G. Laing, Ph.D.
Dr. Lance G. Laing, Ph.D.
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
--
--
Mr. David F. Dalvey
Mr. David F. Dalvey
Independent Director
Independent Director
--
--
Dr. Charlotte Moser, M.D., Ph.D.
Dr. Charlotte Moser, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Leo T. Furcht, M.D.
Dr. Leo T. Furcht, M.D.
Independent Director
Independent Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Brian F. Sullivan
Mr. Brian F. Sullivan
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
3.02M
+0.27%
Mr. Richard J. Nigon
Mr. Richard J. Nigon
Independent Director
Independent Director
101.09K
--
Ms. Vicky Hahne, CPA
Ms. Vicky Hahne, CPA
Chief Financial Officer
Chief Financial Officer
18.86K
+1.63%
Dr. Richard E. Buller, M.D., Ph.D.
Dr. Richard E. Buller, M.D., Ph.D.
Independent Director
Independent Director
7.71K
-0.64%
Dr. Polly A. Murphy, DVM, Ph.D.
Dr. Polly A. Murphy, DVM, Ph.D.
Independent Director
Independent Director
5.00K
--
Dr. Lance G. Laing, Ph.D.
Dr. Lance G. Laing, Ph.D.
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
--
--
収益内訳
データなし
データなし
事業別
地域別
データなし
株主
更新時刻: Fri, May 16
更新時刻: Fri, May 16
株主統計
種類
株主統計
株主統計
比率
Baker Bros. Advisors LP
10.94%
BVF Partners L.P.
8.91%
Sullivan (Brian F)
7.77%
Soleus Capital Management, L.P.
6.61%
Perceptive Advisors LLC
6.07%
Other
59.69%
株主統計
株主統計
比率
Baker Bros. Advisors LP
10.94%
BVF Partners L.P.
8.91%
Sullivan (Brian F)
7.77%
Soleus Capital Management, L.P.
6.61%
Perceptive Advisors LLC
6.07%
Other
59.69%
種類
株主統計
比率
Hedge Fund
37.76%
Investment Advisor
19.79%
Individual Investor
12.29%
Investment Advisor/Hedge Fund
10.89%
Private Equity
6.29%
Venture Capital
4.91%
Research Firm
1.98%
Corporation
0.92%
Pension Fund
0.09%
Other
5.09%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
212
36.06M
95.24%
-3.88M
2025Q1
215
36.05M
95.22%
-4.12M
2024Q4
205
35.54M
95.72%
-3.01M
2024Q3
191
34.97M
94.40%
-1.82M
2024Q2
174
33.96M
98.53%
+4.98M
2024Q1
164
26.84M
87.18%
+3.25M
2023Q4
146
21.83M
92.28%
-1.69M
2023Q3
148
21.82M
100.72%
+289.20K
2023Q2
156
20.45M
95.00%
-276.65K
2023Q1
152
18.61M
87.60%
-1.61M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Baker Bros. Advisors LP
4.26M
11.24%
+1.58M
+58.96%
Mar 31, 2025
BVF Partners L.P.
3.47M
9.15%
--
--
Mar 31, 2025
Sullivan (Brian F)
3.02M
7.99%
+8.15K
+0.27%
Apr 14, 2025
Soleus Capital Management, L.P.
2.57M
6.8%
+9.04K
+0.35%
Mar 31, 2025
Perceptive Advisors LLC
2.36M
6.24%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.03M
5.35%
+10.04K
+0.50%
Mar 31, 2025
The Vanguard Group, Inc.
1.67M
4.42%
+20.26K
+1.23%
Mar 31, 2025
Eventide Asset Management, LLC
1.27M
3.34%
--
--
Mar 31, 2025
New Enterprise Associates (NEA)
1.25M
3.3%
--
--
Mar 31, 2025
Laing (Lance G Ph.D.)
1.25M
3.3%
--
--
Mar 17, 2025
詳細を見る
関連ETF
更新時刻: Sun, Jul 6
更新時刻: Sun, Jul 6
銘柄名
比率
Virtus LifeSci Biotech Clinical Trials ETF
1%
iShares Genomics Immunology and Healthcare ETF
0.93%
ALPS Medical Breakthroughs ETF
0.37%
Tema Oncology ETF
0.26%
iShares Micro-Cap ETF
0.08%
iShares Russell 2000 Growth ETF
0.02%
iShares Russell 2000 ETF
0.01%
Schwab U.S. Small-Cap ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares Hedge Replication ETF
0.01%
詳細を見る
Virtus LifeSci Biotech Clinical Trials ETF
比率1%
iShares Genomics Immunology and Healthcare ETF
比率0.93%
ALPS Medical Breakthroughs ETF
比率0.37%
Tema Oncology ETF
比率0.26%
iShares Micro-Cap ETF
比率0.08%
iShares Russell 2000 Growth ETF
比率0.02%
iShares Russell 2000 ETF
比率0.01%
Schwab U.S. Small-Cap ETF
比率0.01%
Proshares Ultra Russell 2000
比率0.01%
ProShares Hedge Replication ETF
比率0.01%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
